ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2214

Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)

Christopher Redmond1, Moses Kitakule2, Riccardo Castagnoli3, Francesco Licciardi4, Cihan Oguz5, Maria Cecilia Poli6, Aran Son5, Sarah Weber5, Luigi Notarangelo7, Helen Su8 and Daniella Schwartz9, 1National Institutes of Health, Rockville, MD, 2Columbia University, New York, NY, 3National Institute of Allergy and Infectious Diseases, Bethesda, MD, 4OSPEDALE REGINA MARGHERITA, Torino, Italy, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 6Roberto del Rio, Santiago, Chile, 7NIAID/NIH, Bethesda, MD, 8NIH/NIAID, Bethesda, MD, 9National Institutes of Health Clinical Center, Bethesda, MD

Meeting: ACR Convergence 2022

Keywords: Biomarkers, COVID-19, cytokines, Inflammation, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Pediatric Rheumatology – Clinical II: JIA

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable and include fever, gastrointestinal (GI) disease, shock, and Kawasaki Disease (KD). Compared to patients with acute COVID, patients with MIS-C have a distinct immune signature and expansion of TRVB-11 expressing T cells. However, the relationship between immunological and clinical phenotypes of MIS-C is unknown.

Methods: Serum biomarkers, TCR repertoire, and SARS-CoV2-specific T cell responses were measured in a cohort of 76 MIS-C patients. To quantify SARS-CoV2-specific T cell responses, peripheral blood mononuclear cells (PBMCs) were stimulated with SARS-CoV2 peptides and analyzed by flow cytometry, gated on CD45RO+CD4+ and CD45RO+CD8+ T cells. Mann-Whitney testing with multiple comparison adjustment was used for statistical analysis.

Results: Serum biomarkers associated with macrophage and Th1 activation were elevated in MIS-C patients with shock, consistent with previous reports (Fig 1). Diarrhea was associated with a significant reduction in shock-associated serum biomarkers, suggesting a protective effect. There was a trend towards increased SARS-CoV2-induced IFN-y production in CD45RO+CD4+ cells from patients with shock, and towards reduced IFN-y production in patients with diarrhea (Fig 2). Neurologic symptoms and respiratory failure were associated with significantly increased SARS-CoV2-specific CD4+ T cell responses. TRVB-11 usage was highly associated with KD and coronary aneurysms, suggesting a potential biomarker for these manifestations in MIS-C patients (Fig 2).

Conclusion: By identifying novel immunologic associations with the different clinical phenotypes of MIS-C, this study provides insights into the clinical heterogeneity of MIS-C and suggests potential biomarkers for specific manifestations. Shock and respiratory disease are associated with markers of Th1 and macrophage activation. The inverse association of these markers with diarrhea is consistent with reports that diarrhea is also associated with reduced severity of acute COVID-19. Conversely, persistent fecal SARS-CoV2 viremia can increase serum spike protein levels, which is thought to activate a superantigen pathway that promotes TRVB-11 expansion in MIS-C. The association of TRVB-11 with KD suggests that gastrointestinal SARS-CoV2 involvement may be associated with adverse outcomes. Hence, the different clinical manifestations of MIS-C appear to be associated with unique immunophenotypes that could provide biomarkers for patients at risk for severe disease, like shock or KD.

Supporting image 1

Figure 1 Variation in serum biomarker expression in MIS-C patients based on clinical phenotype

Supporting image 2

Figure 2 PBMCs stimulated with SARS-CoV2 peptides, membrane, spike, nucleocapsid (NC), and all of the peptides pooled together. Cytokine expression was analyzed by flow cytometry in CD4+CD45RO+ T cells. IFNy expression was trended higher in patients with shock (2A) and lower in patients with diarrhea (2B). IFNy expression was significantly higher in patients with neurologic symptoms (2C) and IL2 was significantly higher in patients with respiratory compromise (2D). TRVB_11 usage as significantly higher in MIS-C patients who met the criteria for complete on incomplete Kawasaki Disease and those with documented coronary aneurysms (2E).


Disclosures: C. Redmond, None; M. Kitakule, None; R. Castagnoli, None; F. Licciardi, None; C. Oguz, None; M. Poli, None; A. Son, None; S. Weber, None; L. Notarangelo, None; H. Su, Amgen, Pfizer, Eli Lilly, Avanos Medical, Procter & Gamble, Viatris, Zimmer Biomet; D. Schwartz, None.

To cite this abstract in AMA style:

Redmond C, Kitakule M, Castagnoli R, Licciardi F, Oguz C, Poli M, Son A, Weber S, Notarangelo L, Su H, Schwartz D. Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/deep-immune-profiling-uncovers-novel-associations-with-variable-clinical-phenotypes-of-multisystem-inflammatory-syndrome-in-children-mis-c/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deep-immune-profiling-uncovers-novel-associations-with-variable-clinical-phenotypes-of-multisystem-inflammatory-syndrome-in-children-mis-c/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology